Kobayashi Pharmaceutical Co (KOY) Financial Statements
Kobayashi Pharmaceutical Co Financial Overview
Kobayashi Pharmaceutical Co's market cap is currently $2.98B. The company's EPS TTM is $21.87; its P/E ratio is 324.14; and it has a dividend yield of 1.40%. Kobayashi Pharmaceutical Co is estimated to report earnings on November 10, 2026, and the estimated EPS forecast is $0.37. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 165.74B | $ 165.60B | $ 173.46B | $ 166.26B | $ 155.25B |
| Gross Profit | $ 84.71B | $ 87.60B | $ 96.38B | $ 92.33B | $ 88.77B |
| Operating Income | $ 14.92B | $ 24.86B | $ 25.78B | $ 26.67B | $ 26.07B |
| EBITDA | $ 12.52B | $ 21.96B | $ 33.65B | $ 33.33B | $ 32.49B |
| Net Income | $ 3.66B | $ 10.07B | $ 20.34B | $ 20.02B | $ 19.71B |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 70.61B | $ 65.75B | $ 79.84B | $ 104.53B | $ 109.05B |
| Total Assets | $ 275.33B | $ 265.37B | $ 267.47B | $ 255.83B | $ 252.55B |
| Total Debt | $ 678.00M | $ 846.00M | $ 987.00M | $ 792.00M | $ 630.00M |
| Net Debt | $ -61.64B | $ -50.03B | $ -70.55B | $ -95.44B | $ -94.39B |
| Total Liabilities | $ 64.32B | $ 51.89B | $ 62.66B | $ 57.93B | $ 56.95B |
| Stockholders' Equity | $ 211.00B | $ 213.47B | $ 204.82B | $ 197.90B | $ 195.60B |
| Cash Flow | |||||
| Free Cash Flow | $ 12.34B | $ -14.81B | $ 5.60B | $ 17.17B | $ 18.76B |
| Operating Cash Flow | $ 25.59B | $ 11.25B | $ 18.36B | $ 31.91B | $ 22.42B |
| Investing Cash Flow | $ -154.00M | $ -18.41B | $ -19.58B | $ -14.31B | $ 7.99B |
| Financing Cash Flow | $ -7.92B | $ -7.77B | $ -19.46B | $ -20.76B | $ -10.38B |
Currency in JPY
